Pulmonary TB Clinical Trial
Official title:
A Phase 1/2, Active-controlled, Randomized, Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Oral Doses of OPC-167832 Tablets in Subjects With Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00933790 -
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
|
Phase 3 | |
Completed |
NCT04645836 -
Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.
|
N/A | |
Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT03722472 -
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
|
Phase 1 | |
Completed |
NCT00212550 -
Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb
|
N/A | |
Recruiting |
NCT03025516 -
Performance Evaluation of TB Breath- and Cough-testing Platforms
|
N/A | |
Completed |
NCT02961569 -
Comparison Between Two Strategies for the Diagnosis of TB
|
N/A | |
Recruiting |
NCT05426720 -
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
|
||
Recruiting |
NCT04264221 -
Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging
|
N/A | |
Active, not recruiting |
NCT05221502 -
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
|
Phase 2 |